Background Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale.
Conclusions In our international series of dMMR/MSI-H mCRC, early treatment discontinuation of ICIs in the absence of progressive disease can lead to similar long-term disease control compared with a longer treatment duration did not seem detrimental in terms of progression-free survival and overall survival compared with continuing treatment beyond 1 year. Randomized clinical trials to compare short and long treatment duration are now warranted.
Lynch Syndrome Ireland 